The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy

Crit Rev Oncol Hematol. 2018 Dec:132:17-26. doi: 10.1016/j.critrevonc.2018.09.010. Epub 2018 Sep 14.

Abstract

A unique group of genes, encoding tumour associated antigens, known as the Cancer/Testis Antigens (CTAs), have been explored as novel markers of disease progression and as targets of immunotherapy in several cancers, including the haematological malignancy Multiple Myeloma (MM). This review aims to update the knowledge of CTA involvement in MM pathogenesis and how their potential as biomarkers for disease monitoring and targets of immunotherapy has been explored in the MM disease arena. Despite the initial promise of these antigens, their use as immunotherapy targets has not been successful, yet with a greater understanding of their role in disease pathogenesis they may still have a significant role to play as biomarkers of disease and therapeutic targets.

Keywords: CTA; Cascade; Cyclins; Immunotherapy; MRD; Multiple Myeloma.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm / immunology*
  • Antigens, Neoplasm / metabolism*
  • Biomarkers, Tumor / immunology
  • Biomarkers, Tumor / metabolism
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immunotherapy
  • Male
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / therapy*
  • Testis / metabolism*

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor